• Something wrong with this record ?

SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia

C. Chambers, K. Cermakova, YS. Chan, K. Kurtz, K. Wohlan, AH. Lewis, C. Wang, A. Pham, M. Dejmek, M. Sala, M. Loeza Cabrera, R. Aguilar, R. Nencka, HD. Lacorazza, RE. Rau, HC. Hodges

. 2023 ; 83 (7) : 983-996. [pub] 2023Apr04

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23010499

Grant support
R35 GM137996 NIGMS NIH HHS - United States
R01 CA272769 NCI NIH HHS - United States
R01 CA207086 NCI NIH HHS - United States
F31 AI161906 NIAID NIH HHS - United States
S10 OD023469 NIH HHS - United States
P30 EY002520 NEI NIH HHS - United States
S10 OD025240 NIH HHS - United States
S10 OD023469 NIH HHS - United States
S10 OD018033 NIH HHS - United States
S10 RR024574 NCRR NIH HHS - United States
P30 CA125123 NCI NIH HHS - United States

UNLABELLED: In acute myeloid leukemia (AML), SWI/SNF chromatin remodeling complexes sustain leukemic identity by driving high levels of MYC. Previous studies have implicated the hematopoietic transcription factor PU.1 (SPI1) as an important target of SWI/SNF inhibition, but PU.1 is widely regarded to have pioneer-like activity. As a result, many questions have remained regarding the interplay between PU.1 and SWI/SNF in AML as well as normal hematopoiesis. Here we found that PU.1 binds to most of its targets in a SWI/SNF-independent manner and recruits SWI/SNF to promote accessibility for other AML core regulatory factors, including RUNX1, LMO2, and MEIS1. SWI/SNF inhibition in AML cells reduced DNA accessibility and binding of these factors at PU.1 sites and redistributed PU.1 to promoters. Analysis of nontumor hematopoietic cells revealed that similar effects also impair PU.1-dependent B-cell and monocyte populations. Nevertheless, SWI/SNF inhibition induced profound therapeutic response in an immunocompetent AML mouse model as well as in primary human AML samples. In vivo, SWI/SNF inhibition promoted leukemic differentiation and reduced the leukemic stem cell burden in bone marrow but also induced leukopenia. These results reveal a variable therapeutic window for SWI/SNF blockade in AML and highlight important off-tumor effects of such therapies in immunocompetent settings. SIGNIFICANCE: Disruption of PU.1-directed enhancer programs upon SWI/SNF inhibition causes differentiation of AML cells and induces leukopenia of PU.1-dependent B cells and monocytes, revealing the on- and off-tumor effects of SWI/SNF blockade.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010499
003      
CZ-PrNML
005      
20230801132449.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/0008-5472.CAN-22-2129 $2 doi
035    __
$a (PubMed)36662812
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Chambers, Courtney $u Department of Molecular and Cellular Biology, Center for Precision Environmental Health, Baylor College of Medicine, Houston, Texas $u Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas $u Translational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston, Texas $1 https://orcid.org/0000000227548282
245    10
$a SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia / $c C. Chambers, K. Cermakova, YS. Chan, K. Kurtz, K. Wohlan, AH. Lewis, C. Wang, A. Pham, M. Dejmek, M. Sala, M. Loeza Cabrera, R. Aguilar, R. Nencka, HD. Lacorazza, RE. Rau, HC. Hodges
520    9_
$a UNLABELLED: In acute myeloid leukemia (AML), SWI/SNF chromatin remodeling complexes sustain leukemic identity by driving high levels of MYC. Previous studies have implicated the hematopoietic transcription factor PU.1 (SPI1) as an important target of SWI/SNF inhibition, but PU.1 is widely regarded to have pioneer-like activity. As a result, many questions have remained regarding the interplay between PU.1 and SWI/SNF in AML as well as normal hematopoiesis. Here we found that PU.1 binds to most of its targets in a SWI/SNF-independent manner and recruits SWI/SNF to promote accessibility for other AML core regulatory factors, including RUNX1, LMO2, and MEIS1. SWI/SNF inhibition in AML cells reduced DNA accessibility and binding of these factors at PU.1 sites and redistributed PU.1 to promoters. Analysis of nontumor hematopoietic cells revealed that similar effects also impair PU.1-dependent B-cell and monocyte populations. Nevertheless, SWI/SNF inhibition induced profound therapeutic response in an immunocompetent AML mouse model as well as in primary human AML samples. In vivo, SWI/SNF inhibition promoted leukemic differentiation and reduced the leukemic stem cell burden in bone marrow but also induced leukopenia. These results reveal a variable therapeutic window for SWI/SNF blockade in AML and highlight important off-tumor effects of such therapies in immunocompetent settings. SIGNIFICANCE: Disruption of PU.1-directed enhancer programs upon SWI/SNF inhibition causes differentiation of AML cells and induces leukopenia of PU.1-dependent B cells and monocytes, revealing the on- and off-tumor effects of SWI/SNF blockade.
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $x farmakoterapie $x genetika $x metabolismus $7 D015470
650    _2
$a kostní dřeň $x patologie $7 D001853
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a buněčná diferenciace $7 D002454
650    12
$a leukopenie $x genetika $7 D007970
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cermakova, Katerina $u Department of Molecular and Cellular Biology, Center for Precision Environmental Health, Baylor College of Medicine, Houston, Texas $u Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas $1 https://orcid.org/0000000330062213
700    1_
$a Chan, Yuen San $u Department of Molecular and Cellular Biology, Center for Precision Environmental Health, Baylor College of Medicine, Houston, Texas $u Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas $1 https://orcid.org/0000000304677580
700    1_
$a Kurtz, Kristen $u Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas $1 https://orcid.org/0000000152715196
700    1_
$a Wohlan, Katharina $u Department of Molecular and Cellular Biology, Center for Precision Environmental Health, Baylor College of Medicine, Houston, Texas $1 https://orcid.org/0000000291474070
700    1_
$a Lewis, Andrew Henry $u Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas $1 https://orcid.org/0000000245861387
700    1_
$a Wang, Christiana $u Genetics and Genomics Graduate Program, Baylor College of Medicine, Houston, Texas $1 https://orcid.org/000000025275271X
700    1_
$a Pham, Anh $u Department of Bioengineering, Rice University, Houston, Texas $1 https://orcid.org/0000000252149275
700    1_
$a Dejmek, Milan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/000000028195971X
700    1_
$a Sala, Michal $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000315546906
700    1_
$a Loeza Cabrera, Mario $u Department of Molecular and Cellular Biology, Center for Precision Environmental Health, Baylor College of Medicine, Houston, Texas $u Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas $1 https://orcid.org/0000000223977573
700    1_
$a Aguilar, Rogelio $u Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, Texas $1 https://orcid.org/0000000235690713
700    1_
$a Nencka, Radim $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000161670380
700    1_
$a Lacorazza, H Daniel $u Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas $1 https://orcid.org/000000030660617X
700    1_
$a Rau, Rachel E $u Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas $u Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, Texas $1 https://orcid.org/0000000340966603
700    1_
$a Hodges, H Courtney $u Department of Molecular and Cellular Biology, Center for Precision Environmental Health, Baylor College of Medicine, Houston, Texas $u Department of Bioengineering, Rice University, Houston, Texas $u Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas $1 https://orcid.org/000000034441497X
773    0_
$w MED00009437 $t Cancer research $x 1538-7445 $g Roč. 83, č. 7 (2023), s. 983-996
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36662812 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132446 $b ABA008
999    __
$a ok $b bmc $g 1963115 $s 1196764
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 83 $c 7 $d 983-996 $e 2023Apr04 $i 1538-7445 $m Cancer research $n Cancer Res $x MED00009437
GRA    __
$a R35 GM137996 $p NIGMS NIH HHS $2 United States
GRA    __
$a R01 CA272769 $p NCI NIH HHS $2 United States
GRA    __
$a R01 CA207086 $p NCI NIH HHS $2 United States
GRA    __
$a F31 AI161906 $p NIAID NIH HHS $2 United States
GRA    __
$a S10 OD023469 $p NIH HHS $2 United States
GRA    __
$a P30 EY002520 $p NEI NIH HHS $2 United States
GRA    __
$a S10 OD025240 $p NIH HHS $2 United States
GRA    __
$a S10 OD023469 $p NIH HHS $2 United States
GRA    __
$a S10 OD018033 $p NIH HHS $2 United States
GRA    __
$a S10 RR024574 $p NCRR NIH HHS $2 United States
GRA    __
$a P30 CA125123 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options